This promising anticancer activity led to the identification of HNK derivatives with the aim of enhancing its therapeutic activity; among them, Honokiol Hexafluoro (also known as Claisened Hexafluoro; CH) has been shown to be effective against metastatic melanoma [16] and to inhibit DUX4-induced toxicity in an in vitro model of facioscapulohumeral muscular dystrophy (FSHD) [17]. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.